1 2 3
News & Information
Patients should Patients should "Ask-In" on clinical trials participation

African American participation in prostate cancer clinical trials must move from 3-5% range to 10-12% range to determine the effectiveness of new treatments.

FDA Approves Apalutamide: the first treatment for non-metastatic castration-resistant prostate cancer

The U.S. Food and Drug Administration (FDA) approved apalutamide for the treatment of non-metastatic castration-resistant prostate cancer 

Two new treatments have been found for prostate cancer patients who previously had no effective treatment options

Clinical trials have found that Enzalutamide and Apalutamide are both able to significantly delay prostate cancer progression in men with non-metastatic castration-resistant prostate cancer. 
Survivor Network Spotlight - Raymond Fuller, Jr.

During a regular check-up in 2008, Ray Fuller was diagnosed with prostate cancer.  There was no family history of the disease, he said, it “just popped up.”

How dietary fat helps prostate cancer to spread

New research demonstrates how the fat contained within the Western diet, in combination with genetic factors, can cause prostate cancer tumors to spread.

Survivor Network Spotlight - Robbie Robinson

There is no good time to get such news, but it was particularly jarring when Robbie Robinson was diagnosed with prostate cancer in 2002.  

Priority Review of New Drug Application Granted to Apalutamide for CRPC

FDA granted Priority Review to a New Drug Application for apalutamide according to a press release.

Partners